Salarius Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Salarius Pharmaceuticals
SLRX Stock  USD 1.00  0.26  35.14%   
Salarius Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Salarius Pharmaceuticals' valuation are provided below:
Gross Profit
-15.8 M
Market Capitalization
2.1 M
Enterprise Value Revenue
0.1368
Earnings Share
(3.55)
Quarterly Revenue Growth
(1.00)
We have found one hundred twenty available fundamental trend indicators for Salarius Pharmaceuticals, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Salarius Pharmaceuticals current market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 1.9 M in 2025. Enterprise Value is likely to rise to about (378.1 K) in 2025

Salarius Pharmaceuticals Total Revenue

0.0

Check Salarius Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Salarius Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.2 K, Other Operating Expenses of 5.4 M or Research Development of 731.5 K, as well as many indicators such as Price To Sales Ratio of 12.12, Dividend Yield of 0.0086 or PTB Ratio of 1.11. Salarius financial statements analysis is a perfect complement when working with Salarius Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Salarius Stock
Check out the analysis of Salarius Pharmaceuticals Correlation against competitors.
For more information on how to buy Salarius Stock please use our How to Invest in Salarius Pharmaceuticals guide.

Salarius Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets2.9 M3 M30.5 M
Slightly volatile
Other Current Liabilities1.4 M704.8 K1.4 M
Pretty Stable
Total Current Liabilities2.5 M1.5 M2.5 M
Slightly volatile
Property Plant And Equipment Net6.7 K7.1 K115.9 K
Slightly volatile
Accounts Payable1.5 M937 K1.1 M
Slightly volatile
Cash2.3 M2.4 M22.1 M
Slightly volatile
Non Current Assets Total33.6 K35.4 K2.5 M
Pretty Stable
Non Currrent Assets Other33.6 K35.4 K575.1 K
Slightly volatile
Cash And Short Term Investments2.3 M2.4 M27 M
Slightly volatile
Common Stock Total Equity1.6 K2.7 K1.4 K
Slightly volatile
Common Stock Shares Outstanding914.1 K962.2 K3.7 M
Very volatile
Liabilities And Stockholders Equity2.9 M3 M30.5 M
Slightly volatile
Non Current Liabilities Total334.8 K352.4 K13.2 M
Slightly volatile
Other Current Assets905.2 K553 K715 K
Slightly volatile
Other Stockholder Equity68.3 M83.4 M67.3 M
Slightly volatile
Total Liabilities1.4 M1.5 M15.1 M
Slightly volatile
Property Plant And Equipment Gross19.4 K20.4 K120.3 K
Slightly volatile
Total Current Assets2.8 M3 M28 M
Slightly volatile
Common Stock1371441 K
Pretty Stable
Current Deferred Revenue418.6 K440.6 K454.3 K
Pretty Stable
Capital Surpluse35.6 M37.4 M91 M
Slightly volatile
Deferred Long Term Liabilities11.7 K13.1 K14.3 K
Slightly volatile
Property Plant Equipment6.7 K7.1 K158.1 K
Slightly volatile
Net Receivables1.2 M1.9 M981.9 K
Slightly volatile
Intangible Assets10.7 M10.2 M4.1 M
Slightly volatile
Net Invested Capital1.6 M1.7 M20.9 M
Slightly volatile
Net Working Capital1.4 M1.5 M18.7 M
Slightly volatile
Capital Stock1371441.5 K
Slightly volatile
Short and Long Term Debt Total298.2 K221.9 K430.6 K
Slightly volatile
Short and Long Term Debt298.2 K221.9 K430.6 K
Slightly volatile
Short Term Debt298.2 K221.9 K430.6 K
Slightly volatile

Salarius Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization4.2 K4.4 K70.6 K
Very volatile
Other Operating Expenses5.4 M5.7 M15.2 M
Very volatile
Research Development731.5 K770 K7.4 M
Very volatile
Cost Of Revenue4.2 K4.4 K110.4 K
Very volatile
Total Operating Expenses5.4 M5.7 M15.1 M
Very volatile
Interest Income150.6 K158.5 K244.8 K
Pretty Stable
Selling General Administrative7.8 M5 M11.7 M
Slightly volatile
Non Operating Income Net Other667.5 K502.7 K537.3 K
Slightly volatile
Discontinued Operations1.5 K1.6 K1.8 K
Slightly volatile
Selling And Marketing Expenses10 M5.1 M12.7 M
Slightly volatile
Reconciled Depreciation4.2 K4.4 K188.4 K
Slightly volatile
Extraordinary Items1.5 K1.6 K1.8 K
Slightly volatile

Salarius Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation260 K273.7 K3.5 M
Slightly volatile
Begin Period Cash Flow5.6 M5.9 M24.1 M
Slightly volatile
Depreciation4.2 K4.4 K82.5 K
Pretty Stable
Total Cash From Financing Activities1 M1.1 M34.1 M
Slightly volatile
End Period Cash Flow2.3 M2.4 M32.4 M
Slightly volatile
Issuance Of Capital Stock1.5 M1.5 M3.7 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio12.1212.76202.5 K
Slightly volatile
Dividend Yield0.00860.00970.0106
Slightly volatile
Days Sales Outstanding254242117
Slightly volatile
Average Payables937.6 K769.9 K1.2 M
Slightly volatile
Stock Based Compensation To Revenue0.330.353.3137
Slightly volatile
Capex To Depreciation3.0E-43.0E-430.2534
Slightly volatile
Inventory Turnover1.322.071.7878
Slightly volatile
Days Of Inventory On Hand264182216
Slightly volatile
Payables Turnover0.00450.00470.1421
Very volatile
Sales General And Administrative To Revenue1.522.991.7033
Slightly volatile
Average Inventory413.8 K355.8 K385.6 K
Slightly volatile
Research And Ddevelopement To Revenue10.055.3412.5305
Slightly volatile
Capex To Revenue5.0E-46.0E-40.248
Slightly volatile
Cash Per Share2.42.530130.5 K
Slightly volatile
Days Payables Outstanding41.6 K77.3 K42.7 K
Slightly volatile
Income Quality0.780.81160.8755
Pretty Stable
Intangibles To Total Assets0.190.20.1676
Slightly volatile
Net Debt To EBITDA0.380.3971125
Slightly volatile
Current Ratio1.881.976815.6535
Slightly volatile
Receivables Turnover1.481.5649.8545
Slightly volatile
Debt To Equity0.150.14680.0598
Slightly volatile
Capex Per Share0.00.04.5335
Slightly volatile
Average Receivables6.1 K5.7 K5.6 K
Slightly volatile
Revenue Per Share7.648.0420.1401
Pretty Stable
Interest Debt Per Share0.220.230619.6405
Slightly volatile
Debt To Assets0.07710.07340.0414
Slightly volatile
Operating Cycle275309262
Slightly volatile
Days Of Payables Outstanding41.6 K77.3 K42.7 K
Slightly volatile
Ebt Per Ebit0.920.972461.7068
Slightly volatile
Total Debt To Capitalization0.130.1280.0555
Slightly volatile
Debt Equity Ratio0.150.14680.0598
Slightly volatile
Quick Ratio1.881.976815.6392
Slightly volatile
Net Income Per E B T0.790.890.9735
Slightly volatile
Cash Ratio1.531.610913.9087
Slightly volatile
Days Of Inventory Outstanding264182216
Slightly volatile
Days Of Sales Outstanding254242117
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.820.981.0097
Pretty Stable
Fixed Asset Turnover22121095.5644
Slightly volatile
Debt Ratio0.07710.07340.0414
Slightly volatile
Price Sales Ratio12.1212.76202.5 K
Slightly volatile
Asset Turnover0.03850.04060.0564
Slightly volatile
Gross Profit Margin0.590.890.6215
Slightly volatile

Salarius Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.9 M2 M21.6 M
Slightly volatile

Salarius Fundamental Market Drivers

Cash And Short Term Investments2.4 M

Salarius Upcoming Events

25th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
25th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Salarius Pharmaceuticals Financial Statements

Salarius Pharmaceuticals investors use historical fundamental indicators, such as Salarius Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Salarius Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue440.6 K418.6 K
Cost Of Revenue4.4 K4.2 K
Stock Based Compensation To Revenue 0.35  0.33 
Sales General And Administrative To Revenue 2.99  1.52 
Research And Ddevelopement To Revenue 5.34  10.05 
Revenue Per Share 8.04  7.64 
Ebit Per Revenue(6.27)(6.58)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
USOICredit Suisse X Links
ULTYTidal Trust II
CONYYieldMax N Option

Additional Tools for Salarius Stock Analysis

When running Salarius Pharmaceuticals' price analysis, check to measure Salarius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Salarius Pharmaceuticals is operating at the current time. Most of Salarius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Salarius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Salarius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Salarius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY